Web Exclusives

Multiple Myeloma is a complex disease that can significantly affect the health-related quality of life of patients. These quality-of-life issues should be considered when assessing treatment patterns. Read Article ›

The development of new treatments for multiple myeloma would benefit from a systematic consideration of patient preferences. Read Article ›

A subgroup analysis looked at isatuximab plus lenalidomide-bortezomib-dexamethasone as first-line treatment in transplant-eligible newly diagnosed multiple myeloma patients with high-risk cytogenetics. Read Article ›

Longer-term efficacy results with isatuximab in combination with carfilzomib and dexamethasone versus carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma are promising. Read Article ›

Teclistamab in combination with daratumumab may yield improved clinical efficacy in patients with relapsed/refractory multiple myeloma who are heavily pretreated per updated results from the TRIMM-2 trial. Read Article ›

Patients with relapsed/refractory multiple myeloma were treated with subcutaneous isatuximab through an on-body delivery system—a wearable bolus injector that is attached to the patient’s abdomen. Read Article ›

In a follow-up analysis, second-line nivolumab in advanced/recurrent esophageal squamous-cell carcinoma showed significant median overall survival benefit compared with chemotherapy. Read Article ›

Promising antitumor activity and a tolerable safety profile were found in patients with previously treated gastric or gastroesophageal cancer treated with trifluridine/tipiracil combined with ramucirumab. Read Article ›

Insertion-deletion rate and high tumor mutation burden in advanced gastric cancer was found to be associated with favorable progression-free survival and overall survival in patients treated with nivolumab. Read Article ›

Treatment with surufatinib in combination with toripalimab is associated with promising responses and manageable adverse events in previously treated gastric or gastroesophageal junction adenocarcinoma. Read Article ›

Post-hoc analysis of the CheckMate-032 study found PD-L1 expression by combined positive score was more closely associated with nivolumab and ipilimumab therapy efficacy compared with percentage of positive tumor cells PD-L1 expression in advanced gastric/gastroesophageal junction cancer. Read Article ›

Progression-free survival and overall survival improved more after treatment with ramucirumab plus paclitaxel compared with placebo plus paclitaxel in Asian patients with advanced gastric and gastroesophageal junction cancer who were previously treated with chemotherapy. Read Article ›

Page 1 of 17

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to receive the free OPM print publications or weekly e‑Newsletter.

I'd like to receive: